

# Novel Imidazole Biphenyl Derivatives For Ace And Ace Ii Receptor Site Inhibition

Hrudesh Priyadarsan Sahoo<sup>1</sup>, Monalisa Gochhi<sup>2</sup>, Kadambari Panda<sup>3</sup>, Bijayabharati Sahoo<sup>4</sup>, Toffa Das Mohapatra<sup>5</sup>, Dr. Nityananda Sahoo<sup>6</sup>

<sup>1</sup>Assistant Professor, Department of Pharmacology, School of Pharmacy Centurion University of Technology and Management, Gopalpur, Odisha, India Email id- [hrudeshpriyadarsan97@gmail.com](mailto:hrudeshpriyadarsan97@gmail.com)

<sup>2</sup>Assistant Professor, Department of Pharmacology Sri Jayadev College of Pharmaceutical Sciences, Naharkanta, Bhubaneswar, India

<sup>3</sup>Assistant Professor, Department of Pharmacology Sri Jayadev College of Pharmaceutical Sciences, Naharakanta, Bhubaneswar, India

<sup>4</sup>Assistant Professor, Department of Pharmaceutical Analysis Nityananda College of Pharmacy, Balasore, Odisha, India

<sup>5</sup>Assistant Professor, Department of Pharmacology Dadhichi College of Pharmacy, Cuttack, Odisha, India

<sup>6</sup>Professor, Department of Pharmaceutical Chemistry, School of Pharmacy Centurion University of Technology and Management, Gopalpur, Balasore, Odisha, India  
DOI: 10.47750/pnr.2022.13.S07.599

## Abstract

Angiotensin converting enzyme (ACE) and  $\alpha$ -amylase inhibitors were synthesized using 40-(bromomethyl)-biphenyl-2-carbonitrile 1 and various cyclic secondary amines (a–h). The nitrile group appended to biphenyl was converted into tetrazole 3a–3h and the tetrazole was ring transformed into 1,3,4-oxadiazole derivatives 4a–4h. Some of the compounds have exhibited significant ACE and  $\alpha$ -amylase inhibition.


**Keywords-** Biphenyl, Tetrazole, 1,3,4-Oxadiazole, ACE,  $\alpha$ -Amylase.

## INTRODUCTION

Special attention is required during the management of hypertension in diabetes. The presence of hypertension in diabetic patients substantially increases the risks such as coronary heart disease, stroke, nephropathy, and retinopathy. When hypertension coexists with diabetes, the risk of cardiovascular disease is increased by 75 % (Patel, 1985; Sowers et al., 2001). In view of this, angiotensin converting enzyme (ACE)-inhibitors and angiotensin II receptor blockers have many benefits in diabetic hypertensive patients. Biphenyl is the key moiety in all the sartans (Kumar et al., 2010; Wang et al., 2011; Hadizad et al., 2009, Zupancic et al., 2010; Park et al., 2010; Larsen et al., 1994) which are angiotensin II receptor antagonists useful in the treatment of hypertension, heart diseases, heart attack, and bladder diseases (Fig. 1). Tetrazole functions as a carboxylic acid bioisostere which can impart greater metabolic stability and increased absorption relative to the carboxylic acid. It has a similar pKa to CO<sub>2</sub>H group and as part of a drug molecule it offers the potential of a longer in vivo half-life. Its negative charge delocalizes over all four nitrogens which translate into derivatives with a higher clog P and thus better oral bioavailability and cell penetration. Additionally, the four nitrogen atoms offer a greater opportunity for H-bond donor/acceptor interactions and the p-electron system of the aromatic ring can have additional hydrophobic interactions, both of which can provide strong receptor binding and applications as antihypertensive, antiallergic, antibiotic, and anticonvulsant agents (Myznikov et al., 2007; Mavromoustakos et al., 1999; Toney et al., 1998; Sherif Rostom et al., 2009; Mulwad et al., 2008; Upadhyaya et al., 2004; Mohite et al., 2010; Bhaskar and Mohite, 2010; De Souza et al., 2005). 1,3,4-Oxadiazole derivatives have been found to exhibit diverse pharmacological properties such as antimicrobial, anti-HIV (Ingole et al., 2007; El-Emam et al., 2004), anti-tubercular (Franski, 2005), anti-malarial (Kagthara et al., 1999), analgesic (Reddy et al., 1997),

anti-inflammatory (Amir et al., 2007), anticonvulsant (Khan et al., 2001), hypoglycemic (O'Neal et al., 1962), antifungal (Mishra et al., 2005), and other biological properties such as genotoxic (Maslat et al., 2002) and lipid peroxidation inhibition (Farghaly et al., 2000). It was envisaged that if two pharmacophores linked together would generate novel molecular templates which are likely to exhibit interesting biological properties (Tegginamath et al., 2013). All the above facts encouraged us to synthesize novel molecules by reacting 40-(bromomethyl)-biphenyl-2-carbonitrile 1 and cyclic secondary amines (a–h). The nitrile group on the biphenyl moiety was converted into tetrazole and further ring transformed into 1,3,4-oxadiazole. The


newly synthesized biphenyl derivatives of cyclic secondary amines appended to tetrazole 3a–3h and to 1,3,4-oxadiazole 4a–4h were subjected to OSIRIS property explorer to find out the drug-likeness and hence drug score values were calculated to analyze their oral bioavailability. Also, the title compounds 3a–3h and 4a–4h were subjected to inhibition of ACE and  $\alpha$ -amylase to substantiate the OSIRIS property explorer results.




**Fig. 1** Angiotensin receptor antagonists (Sartans)

**(i) Chemistry**—The reaction of 40-(bromomethyl)-biphenyl-2-carbonitrile 1 with cyclic secondary amines (a–h) in presence of anhydrous  $K_2CO_3$  in acetone afforded 2a–2h. The compounds 2a–2h when refluxed with sodiumazide and triethylamine hydrochloride in toluene gave tetrazole 3a–3h. The tetrazole ring of compounds 3a–3h was ring transformed into 1,3,4-oxadiazole (4a–4h) which was achieved by refluxing with acetic anhydride (Scheme 1). The mechanism of ring transformation of tetrazoles to 1,3,4-oxadiazoles is depicted in Scheme 2 (Koldobski et al., 1981). It involved the initial acetylation of 2H-tetrazole 3a–3h which further undergoes the ring opening followed by elimination of a molecule of nitrogen to form a carbene. Carbene then undergoes insertion across the carbonyl group to form 1,3,4-oxadiazole derivatives 4a–4h.

**(ii) Results and discussion**—The compounds 2a–2h have shown a characteristic stretching band at 2,150–2,220  $cm^{-1}$  due to the nitrile group. The protons on the methylene group resonated as singlet in the range of 3.81–5.20 ppm. The compounds 3a–3h and 4a–4h with methylene protons spaced between the biphenyl group and nitrogen heterocycles appeared as a singlet for two protons in the range of 3.80–5.99 ppm. The remaining protons in the various heterocycles attached to biphenyl rings appeared in their respective range. The number of signals in  $^{13}C$ NMR spectra of all the compounds was in consistent with the number of magnetically non-equivalent carbon atoms. Also the mass spectral studies indicated the  $m/z$  value corresponding to the molecular mass of the respective compounds. All these data are provided in the ‘‘Experimental procedure’’ section. We have recently reported the single crystal analyses of compound 3g (Meti et al., 2013).



**Scheme 1 Protocol for the synthesis of biphenyl derivatives**



**Scheme 2 Mechanism for ring transformation of tetrazole 3a–3h into oxadiazole 4a–4h**

### (iii) Pharmacological assay

**(a)Molecular Osiris property explorer**-A novel molecule is subjected for verification of parameters set by Lipinski's rule of five to analyze its drug-likeness and drug score (Lipinski, 2004; Emami et al., 2011; Taj et al., 2011, 2012). The title compounds do not violate the Lipinski rule and they fall well in the range (Table 1). All the title compounds showed clog P well within the range and also molecular weights less than 500. The drug-likeness ranged from -3.01 to 8.54 whereas, the drug score ranged from 0.23 to 0.78. The drug-likeness and drug score was found to be more in tetrazole 3a–3h and decreased after ring transformation into compounds viz., 1,3,4-oxadiazole derivatives 4a–4h. Interestingly, this observation is in correlation with the *in vitro* ACE and  $\alpha$ -amylase inhibition assays.


**(b) In vitro ACE inhibition**-The activity of rennin–angiotensin–aldosterone system is to be reduced to maintain the blood pressure. This is so because rennin a protein which is released from the kidney cells produces another protein, angiotensin which induces the adrenal gland to produce aldosterone. This system is activated in response to fall in blood pressure as well as problems with salt–water balance of the body by decreasing sodium ion concentration in the kidney.

In this situation rennin cuts off all aminoacids except the first ten residues of angiotensin (decapeptide). These ten residues are known as angiotensin I. ACE further removes two residues and converts angiotensin I into angiotensin II. Angiotensin II a powerful vasoconstrictor which stimulates the aldosterone secretion. Aldosterone increases reabsorption of Na<sup>+</sup> from distal as well as collecting tubule and hence leads to edema and hypertension. Therefore, ACE is the main target for reducing the blood pressure in the treatment of hypertension thus lowering the arteriolar resistance, increasing the venous capacity, increasing cardiac output, cardiac index, stroke work, and lowering the renovascular resistance (Haslett et al., 1999; Chaudhuri, 1993). As per the information to the authors, no report is found in which the angiotensin receptor antagonists (ARB) were used to inhibit the ACE enzyme. Therefore, in the present work we have made an effort to use the tetrazole derivatives of biphenyl attached to various heterocycles viz., the compounds 3a–3h and 4a–4h (ring transformed products of tetrazole derivatives) which are the structural analogs of angiotensin II receptor antagonists (sartans) for their inhibitory activities of ACE.


Entry no.	<i>clog P</i>	Drug-likeness	Drug score
3a	1.77	2.77	0.36
3b	2.03	1.81	0.73
3c	1.74	0.41	0.62
3d	1.92	3.30	0.75
3e	2.20	8.54	0.78
3f	1.62	3.23	0.75
3g	2.08	1.99	0.70
3h	2.13	4.67	0.66
4a	2.82	2.33	0.33
4b	3.08	1.17	0.65
4c	2.79	-0.029	0.53
4d	2.97	2.74	0.70
4e	3.25	8.02	0.73
4f	2.67	2.83	0.7
4g	3.13	1.53	0.63
4h	3.18	4.29	0.61

**Table 1** Osiris properties of molecules 3a–3h and 4a–4h

In view of this, the compounds 3a–3h and 4a–4h were used in three concentrations viz., 1, 5, and 10 lg to inhibit the ACE. It was found that the compound 3b (with imidazole) exhibited the potent inhibition at 10 lg (80 %). Also, the compounds 3c (1,2,4-triazole), 3d (piperazine), and 3e (N-methylpiperazine) have exhibited stronger ACE inhibition at higher concentration (10 lg) viz., 80, 83, and 92 %, respectively. The remaining compounds did not show any activity. It is quite interesting to note that the compounds 4a–4h did not show any ACE inhibition at all the concentrations. This has obviously indicated that tetrazole moiety is a requirement for the biphenyl derivatives to exhibit the inhibition. The inhibitory potencies of the compounds 3a–3h and 4a–4h are represented in Fig. 2.



**Fig. 2** ACE inhibition by tetrazoles 3a–3h and oxadiazoles 4a–4h



**Fig. 3** a-Amylase inhibition by tetrazoles 3a–3h and oxadiazoles 4a–4h

(c) **In vitro a-amylase inhibition**-The compounds 3a–3h and 4a–4h were also evaluated for their inhibitory effects against a-amylase to analyze the possible use of these compounds as antihyperglycemic agents. All the compounds were tested at three concentrations viz., 100, 250, and 500 µg. It was observed that the tetrazole derivatives with the heterocycles 1,3-thiazolidine- 2,5-dione (3a), imidazole (3b), 1,2,4-triazole (3c), piperazine (3d), and N-methylpiperazine (3e) have exhibited

excellent inhibition of a-amylase and hence the activity of this enzyme is restricted only to 35.84–41.62 % as compared to control (100 %). Thus, the hydrolysis of starch is decreased in presence of these compounds at 500 µg dose level. However, the compounds 3g and 3h with morpholine and piperidine-4-carboxylic acid moieties, respectively, did not show significant activities. 1,3,4-Oxadiazole derivatives 4a–4h did not exhibit considerable a-amylase inhibition. Hence, the activity of this enzyme was more at all the concentration (compared to control) as represented in the bar graph in Fig. 3.

## EXPERIMENTAL PROCEDURE

(i) **Chemistry**- Melting points were determined in open capillaries. FTIR spectra were recorded in KBr pellets on a Perkin-Elmer Paragon 1000 PC spectrometer. The <sup>1</sup>H NMR spectral analyses were carried out in Bruker Avance-300 spectrometer (300 MHz) and <sup>13</sup>C NMR spectral analyses were carried out in Bruker-400 (400 MHz) instrument using TMS as an internal standard. Mass spectra were recorded on Shimadzu Japan QP2010 S model spectrometer. The elemental analyses data were obtained from Heraeus CHN rapid analyzer. Chemicals were purchased from Aldrich and used without purification.

(ii) **General procedure for the preparation of compounds (2a–2h)**- A mixture of 40-(bromomethyl)-biphenyl-2-carbonitrile 1 (1.0 mol), cyclic secondary amines (a–h, 1.1 mol), and anhydrous K<sub>2</sub>CO<sub>3</sub> (1.4 mol) in acetone (25 ml) were stirred for 24 h at 27–30 °C and the reaction was monitored by TLC. After completion of reaction, acetone was evaporated and poured into water, stirred well and extracted with DCM. DCM layer was washed with water and dried over anhydrous sodiumsulphate to get yellowish powder which was recrystallized using acetone–water mixture (yield 60–75 %).

(a) **40-[(2,4-Dioxo-1,3-thiazolidin-3-yl)methyl]biphenyl-2- carbonitrile (2a)**- Pale yellow powder, mp. 134–135 °C. IR (KBr): 1750 (S– C=O), 1681 (N–C=O), 2228 (CN) cm<sup>-1</sup>; <sup>1</sup>H NMR(300 MHz, DMSO-d<sub>6</sub>): δ 3.85 (s, 2H, CH<sub>2</sub>), 4.71 (s, 2H, CH<sub>2</sub>), 7.32 (d, 2H, J = 6.9 Hz, ArH), 7.41 (d, 2H, J = 6.9 Hz, ArH), 7.51–7.65 (m, 4H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 33.7, 44.7, 110.8, 118.0, 127.5, 128.9, 129.1, 132.7, 133.5, 135.3, 137.9, 144.5, 171.0, 171.5; MS (m/z, 70 eV): 308, 282, 280, 255, 234, 209, 206, 192, 181, 167, 102, 91, 77; Anal. Calcd. For C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S: C, 66.22; H, 3.92; N, 9.08 %. Found: C, 66.20; H, 3.87; N, 9.11 %.

(b) **40-(1H-Imidazol-1-yl-methyl)-biphenyl-2-carbonitrile (2b)**- Colorless crystals, mp. 212–214 °C; IR (KBr): 2220 (CN stretching), 3040, 1550 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.18 (s, 2H, CH<sub>2</sub>), 6.95 (d, 1H, imidazole C5-H), 7.05 (d, 1H, imidazole C4-H), 7.20 (d, 2H, ArH), 7.45 (d, 2H, ArH), 7.52–7.68 (m, 4H, ArH), 7.77 (s, 1H, imidazole C2-H);

<sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 49.13 (CH<sub>2</sub>), 113.50, 121.21, 126.8, 127.5, 128.7, 129.0, 129.4, 129.7, 135.4, 135.7, 135.9, 137.20, 141.6, 145.23; MS (m/z, 70 eV): 259, 192, 165, 63, 40; CHN Analysis: Calculated for C<sub>17</sub>H<sub>13</sub>N<sub>3</sub>: C, 78.73; H, 5.05; N, 16.22. Found: C, 78.69; H, 5.02; N, 16.20.

**(c) 40-(4H-1,2,4-Triazol-1-yl-methyl)-biphenyl-2- carbonitrile (2c)-** Colorless crystals, mp. 240–242 °C; IR (KBr): 2210 (CN stretching), 1500 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.29 (s, 2H, CH<sub>2</sub>), 7.30 (d, 2H, ArH), 7.50 (d, 2H, ArH), 7.65–7.74 (m, 4H, ArH), 8.50 (s, 2H, triazole C–H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 47.33 (CH<sub>2</sub>), 110.50, 127.5, 128.8, 128.7, 129.0, 129.4, 129.7, 135.4, 135.7, 135.9, 137.20, 148.61, 152.13; MS (m/z, 70 eV): 260, 192, 68; CHN Analysis: Calculated for C<sub>16</sub>H<sub>12</sub>N<sub>4</sub>: C, 73.81; H, 4.65; N, 21.63. Found: C, 73.76; H, 4.61; N, 21.61.

**(d) 40-(Piperazin-1-yl)-methyl-biphenyl-2-carbonitrile (2d)-** Colorless crystals, mp. 190–192 °C, IR (KBr): 2180 (CN stretching), 3450 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.12–3.10 (m, 8H, piperazineCH<sub>2</sub>), 3.81 (s, 2H, CH<sub>2</sub>), 7.42 (d, 2H, ArH), 7.50 (d, 2H, ArH), 7.67–7.80 (m, 4H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 45.43 (N–CH<sub>2</sub>), 52.21 (N–CH<sub>2</sub>), 63.12 (CH<sub>2</sub>), 112.00, 120.86, 127.5, 128.5, 128.7, 129.0, 129.7, 135.4, 135.7, 135.9, 137.20, 146.61; MS (m/z, 70 eV): 277, 248 192, 99; CHN Analysis: Calculated for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>: C, 77.97; H, 6.89; N, 15.17. Found: C, 77.95; H, 6.88; N, 15.14.

**(e) 40-[(4-Methylpiperazin-1-yl)-methyl]biphenyl-2- carbonitrile (2e)-** Pale yellow crystals, mp. 50–52 °C, IR (KBr): 3078, 2895, 2200 (CN), 1465 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.25–2.81 (m, 8H, CH<sub>2</sub>), 2.92 (s, 3H, CH<sub>3</sub>), 3.81 (s, 2H, CH<sub>2</sub>), 7.51 (d, 2H, ArH), 7.68 (d, 2H, ArH), 7.74–7.91 (m, 4H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 46.48 (N–CH<sub>3</sub>), 52.27 (N–CH<sub>2</sub>), 54.32 (N–CH<sub>2</sub>), 63.62 (CH<sub>2</sub>), 113.0, 126.8, 128.5, 128.7, 129.0, 129.4, 130.7, 135.4, 135.7, 137.20, 146.61; MS (m/z, 70 eV): 291, 192, 99; CHN Analysis: Calculated for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>: C, 78.33; H, 7.23; N, 14.42. Found: C, 78.30; H, 7.23; N, 14.41.

**(f) 2-[2-{4-(2-Cyanobiphenyl)-methyl-piperazin-1-yl}ethoxy]ethanol (2f)-** Pale brown oil, IR (KBr): 3545 (OH), 2220 (CN stretching), 3040, 1500 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.06 (t, 4H, piperazine CH<sub>2</sub>), 2.32 (t, 4H, piperazine CH<sub>2</sub>), 3.44 (s, 2H, CH<sub>2</sub>), 3.56–3.80 (m, 8H, CH<sub>2</sub>), 7.35–7.80 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 52.20 (N–CH<sub>2</sub>), 53.22 (N–CH<sub>2</sub>), 55.41, 61.25, 63.62 (CH<sub>2</sub>), 69.32, 72.64, 110.31, 127.6, 128.9, 129.0, 129.4, 129.7, 135.4, 135.7, 135.9, 137.20, 148.90; MS (m/z, 70 eV): 366, 321, 277, 99; CHN Analysis: Calculated for C<sub>22</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>: C, 72.30; H, 7.40; N, 11.52. Found: C, 72.28; H, 7.38; N, 11.49.

**(g) 40-(Morpholin-4-yl-methyl)biphenyl-2-carbonitrile (2g)-** Colorless crystals, mp. 75–77 °C, IR (KBr): 2175 (CN stretching), 1500 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.93 (t, 4H, morpholine CH<sub>2</sub>), 3.8 (s, 2H, CH<sub>2</sub>), 3.94 (t, 4H, morpholine CH<sub>2</sub>), 7.42–7.84 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 52.02 (N–CH<sub>2</sub>), 63.72 (CH<sub>2</sub>), 66.82 (O–CH<sub>2</sub>), 117.91, 126.8, 128.9, 128.7, 129.0, 129.7, 135.4, 135.7, 135.9, 137.20, 144.69; MS (m/z, 70 eV): 278, 250, 192; CHN Analysis: Calculated for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O: C, 77.65; H, 6.49; N, 10.08. Found: C, 77.64; H, 6.47; N, 10.06.

**(h) 1-[(20-Cyanobiphenyl-4-yl-methyl)piperidine-4-carboxylic acid (2h)-** Brown oil, IR (KBr): 3550 (OH), 2225 (CN), 1725 (C=O) cm<sup>-1</sup>, <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.95 (m, 4H, CH<sub>2</sub>), 2.1–2.3 (t, 4H, CH<sub>2</sub>), 2.69 (m, 1H, CH), 3.42 (d, 2H, CH<sub>2</sub>), 7.41–7.75 (m, 8H, ArH), 11.5 (bs, 1H, NH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 28.36 (C–CH<sub>2</sub>), 39.64, 51.54 (N–CH<sub>2</sub>), 63.65 (CH<sub>2</sub>), 119.79, 127.9, 128.7, 129.0, 129.4, 129.7, 135.4, 135.7, 135.9, 137.20, 144.69, 182.39 (COOH); MS (m/z, 70 eV): 320, 276, 192, 251, 84; CHN Analysis: Calculated for C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>: C, 74.94; H, 6.27; N, 8.77. Found: C, 74.92; H, 6.25; N, 8.74.

**(iii) General procedure for the preparation of compounds (3a–3h)-** A mixture of compounds 2a–2h (4.0 mol), sodiumazide (4.2 mol) triethylaminehydrochloride (4.2 mol) in toluene (35 ml) was refluxed for 48 h. The reaction mass was then cooled to room temperature and extracted with aqueous NaOH solution (5 %). The pH of aqueous solution was adjusted to neutral with conc. HCl and crude solid formed was filtered and washed with distilled water. Recrystallization using aqueous ethanol gave crystals of 3a–3h (yield 50–55 %).

**(a) 5-[2-{4-(2,4-Dioxo-1,3-thiazolidin-3-yl)-methyl}- biphenyl]-1H-tetrazole (3a)-** Off white solid, mp. 216–218 °C; IR (KBr): 3411 (NH), 1749, (S–C=O), 1670 (N–C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 3.72 (s, 2H, CH<sub>2</sub>), 4.67 (s, 2H, CH<sub>2</sub>), 7.12 (d, 2H, J = 8.05 Hz, ArH), 7.36 (d, 2H, J = 8.05 Hz, ArH), 7.45–7.62 (m, 4H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 35.1 (thiadiazole CH<sub>2</sub>), 44.2 (CH<sub>2</sub>), 127.5, 127.7, 128.0, 128.2, 129.3, 129.7, 135.1, 134.5, 135.4, 140.6, 163.5, 165.0, 168.0; MS (m/z): 351, 350, 322, 248, 206, 205, 192, 178, 165, 152, 139, 118, 102, 89, 77, 62, 47, 46, 42; Anal. Calcd. For C<sub>17</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub>S: C, 58.11; H, 3.73; N, 19.93. Found: C, 58.05; H, 3.68; N, 19.90 %.

**(b) 5-[40-(1H-Imidazol-1-yl-methyl)biphenyl-2-yl]-1Htetrazole (3b)-** Pale yellow crystals, mp. 190–192 °C; IR (KBr): 3063, 1645 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.26 (s, 2H, CH<sub>2</sub>), 6.64 (1H, s, imidazole C5-H) 6.97 (d, 1H, imidazole C4-H), 7.38–7.72 (m, 8H, ArH), 7.75 (s, 1H, imidazole C2-H); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 48.0 (CH<sub>2</sub>), 120.4, 127.2, 127.9, 128.0, 128.2, 128.5, 129.0, 129.2, 133, 133.2, 133.7, 135.4, 137.0, 166.5; MS (m/z, 70 eV): 301, 235, 207, 178, 165, 152, 63, 44, 40; CHN Analysis: Calculated for C<sub>17</sub>H<sub>14</sub>N<sub>6</sub>: C, 67.53; H, 4.64; N, 27.83. Found: C, 67.51; H, 4.66; N, 27.82.

(c) **5-[40-(4H-1,2,4-Triazol-1-yl-methyl)biphenyl-2-yl]-1H-tetrazole (3c)**- Colorless crystals, mp. 205–207 °C; IR (KBr): 3083, 1955, 1095 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.33 (s, 2H, CH<sub>2</sub>), 7.73–7.82 (m, 8H, ArH), 8.5 (s, 2H, triazole H); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 51.60 (CH<sub>2</sub>), 127.6, 127.8, 129.02, 129.22, 130.56, 131.03, 135.44, 135.82, 138.82, 143.26, 144.27, 151.2, 158.00; MS (m/z, 70 eV): 303, 234, 207, 178, 166, 152, 63, 44; CHN Analysis: Calculated for C<sub>16</sub>H<sub>13</sub>N<sub>7</sub>: C, 63.35; H, 4.31; N, 32.34. Found: C, 63.32; H, 4.29; N, 32.32.

(d) **1-[[20-(1H-Tetrazol-5-yl)biphenyl-4-yl] methyl] piperazine (3d)**- Pale yellow crystals, mp. 182–184 °C; IR (KBr): 3389 (NH), 3028, 1658 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.18 (t, 4H, CH<sub>2</sub>), 2.78 (t, 4H, CH<sub>2</sub>), 3.85 (s, 2H, CH<sub>2</sub>), 7.4–7.85 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 48.00 (N-CH<sub>2</sub>), 53.05 (N-CH<sub>2</sub>), 60.19 (CH<sub>2</sub>), 127.20, 128.02, 128.18, 128.25, 129.50, 129.61, 133.05, 134.92, 135.10, 135.81, 162.00; MS (m/z, 70 eV): 320, 280, 250, 192, 154, 89, 63, 44; CHN Analysis: Calculated for C<sub>18</sub>H<sub>20</sub>N<sub>6</sub>: C, 67.48; H, 6.25; N, 26.27. Found C, 67.47; H, 6.24; N, 26.28.

(e) **1-Methyl-4-[[20-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl] piperazine (3e)**- Brown crystals, mp. 155–157 °C; IR (KBr): 2988, 1642 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.35–2.46 (m, 8H, piperazine CH<sub>2</sub>), 3.56 (s, 2H, CH<sub>2</sub>), 3.85 (s, 3H, CH<sub>3</sub>), 7.5–7.94 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 40.5 (CH<sub>2</sub>), 51.2, 57.4, 62.0, 127.1, 128.4, 128.7, 128.9, 129.6, 129.9, 135.5, 135.7, 135.8, 136.2, 168.2; MS (m/z, 70 eV): 334, 291, 262, 242, 235, 192, 165, 99, 56, 43; CHN Analysis: Calculated for C<sub>19</sub>H<sub>22</sub>N<sub>6</sub>: C, 68.24; H, 6.61; N, 25.15. Found C, 68.23; H, 6.59; N, 25.13.

(f) **2-[2-(4-20-(Tetrazol-4-yl)-biphenyl)-piperazin-1-yl]ethoxy]ethanol (3f)**- Brown crystals, mp. 185–187 °C, IR (KBr): 3515, 3010, 1522 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.32–2.41 (m, 8H, piperazine CH<sub>2</sub>), 2.54 (t, 2H, N-CH<sub>2</sub>), 3.25 (t, 2H, CH<sub>2</sub>-O), 3.31 (t, 2H, O-CH<sub>2</sub>), 3.40 (t, 2H, CH<sub>2</sub>OH), 3.58 (s, 2H, CH<sub>2</sub>), 7.15–7.68 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 55.0, 58.0, 59.7, 61.9 (CH<sub>2</sub>), 62.5, 70.00, 73.5, 127.7, 128.0, 128.2, 128.4, 129.3, 129.4, 134.5, 135.0, 135.1, 135.4, 162.5; MS (m/z, 70 eV): 409, 366, 320, 221, 192, 99, 44, 40; CHN Analysis: Calculated for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>: C, 64.68; H, 6.87; N, 20.59. Found C, 64.66; H, 6.85; N, 20.60.

(g) **4-[[20-(1H-Tetrazol-5-yl)-biphenyl-4-yl]methyl]morpholine (3g)**- Colorless crystals, mp. 200–202 °C, IR (KBr): 2990, 1650 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.95 (t, 4H, morpholine N-CH<sub>2</sub>), 3.74 (s, 4H, morpholine O-CH<sub>2</sub>), 4.02 (s, 2H, CH<sub>2</sub>), 7.40–7.84 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 50.0, 55.6, 64.0 (CH<sub>2</sub>), 126.9, 127.2, 128.2, 128.5, 128.2, 128.7, 129.5, 129.8, 134.3, 135.8, 136.0, 167.0; MS (m/z, 70 eV): 321, 293, 192, 84, 63, 44, 40; CHN Analysis: Calculated for C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>: C, 67.25; H, 5.92; N, 21.82. Found: C, 67.26; H, 5.90; N, 21.79.

(h) **1-[[20-(1H-Tetrazol-5-yl)biphenyl-4-yl] methyl]piperidine- 4-carboxylic acid (3h)**- Pale yellow crystals, mp. 183–185 °C; IR (KBr): 3455, 3078, 1718 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.05 (m, 4H, CH<sub>2</sub>), 2.20–2.35 (t, 4H, CH<sub>2</sub>), 3.12 (m, 1H, CH), 3.84 (s, 2H, CH<sub>2</sub>), 7.12–7.64 (m, 8H, ArH), 10.25 (bs, 1H, OH); <sup>13</sup>C NMR (300 MHz, DMSO-d<sub>6</sub>): δ 29.2, 41.7, 51.4, 60.4 (CH<sub>2</sub>), 127.6, 128.0, 128.2, 128.4, 129.3, 129.4, 134.5, 135.0, 135.1, 135.4, 168.9, 178.00; MS (m/z, 70 eV): 364, 318, 277, 192, 86, 65, 44, 40; CHN Analysis: Calculated for C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>: C, 66.08; H, 5.81; N, 19.29. Found: C, 66.05; H, 5.82; N, 19.30.

(iv) **General procedure for the preparation of compounds (4a–4h)**- A mixture of compound (3a–3h, 0.1 mol) and acetic anhydride (20 ml) were refluxed for 2 h and cooled to room temperature, poured into ice cold water and kept for about 10 h at 25–30 °C. The aqueous solution was then extracted with ethyl acetate (20 ml), washed with water (50 ml) and distilled to get the crude solid which was crystallized using aqueous acetone (yield 55–60 %).

(a) **3-[[20-(5-Methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl]methyl]-1,3-thiazolidine-2,4-dione (4a)**- Off white solid, mp. 60–62 °C; IR (KBr): 1747 (S-C=O), 1673 (N-C=O), 1650, 1485 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.95 (s, 3H, CH<sub>3</sub>) 3.72 (s, 2H, CH<sub>2</sub>), 4.66 (s, 2H, CH<sub>2</sub>), 7.12 (d, 2H, J = 8.05 Hz, ArH), 7.35 (d, 2H, J = 8.05 Hz, ArH), 7.45–7.60 (m, 4H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 14.3 (CH<sub>3</sub>), 37.5 (thiadiazole CH<sub>2</sub>), 46.00 (CH<sub>2</sub>), 127.8, 128.5, 128.7, 129.0, 129.4, 129.7, 135.4, 135.7, 135.9, 141.6, 167.8 (oxadiazole C<sub>2</sub>), 169.7 (oxadiazole C<sub>5</sub>), 171.6 (CO), 173.2 (CO); MS (m/z, 70 eV): 366, 323, 263, 180, 152, 89.49, 44; CHN Analysis: Calculated for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S: C, 62.45; H, 4.14; N, 11.50. Found C, 62.40; H, 4.15; N, 11.49.

(b) **2-[40-(1H-Imidazol-1-yl-methyl)biphenyl-2-yl]-5-methyl- 1,3,4-oxadiazole (4b)**- Pale green crystals, mp. 62–64 °C; IR (KBr): 1650, 1485 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, δ ppm): 2.15 (s, 3H, CH<sub>3</sub>), 5.25 (s, 2H, CH<sub>2</sub>), 6.9 (d, 1H, imidazole C<sub>5</sub>-H), 7.05 (d, 1H, imidazole C<sub>4</sub>-H), 7.15 (d, 2H, ArH), 7.20 (d, 2H, ArH), 7.32–7.55 (m, 4H, ArH), 7.68 (s, 1H, imidazole C<sub>2</sub>-H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 9.97 (CH<sub>3</sub>), 50.3 (CH<sub>2</sub>), 121.2 (imidazole C<sub>5</sub>), 125.8, 127.0, 127.1 (imidazole C<sub>4</sub>), 127.6, 128.3, 128.6, 129.0, 129.5, 133.0, 135.1, 135.5, 137.8 (imidazole C<sub>2</sub>), 165.0 (oxadiazole C<sub>2</sub>), 166.7 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 317, 275, 242, 220, 155, 68; CHN Analysis: Calculated for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O: C, 72.11; H, 5.08; N, 17.72. Found C, 72.09; H, 5.10; N, 17.69.

(c) **2-Methyl-5-[40-(4H-1,2,4-triazol-1-yl-methyl)biphenyl-2-yl]-1,3,4-oxadiazole (4c)**- Colorless crystals, mp. 80–82 °C; IR (KBr): 3515, 1647 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35 (s, 3H, CH<sub>3</sub>), 4.95 (s, 2H, CH<sub>2</sub>), 7.20 (d, 2H,

ArH), 7.42 (d, 2H, ArH), 7.34–7.58 (m, 4H, ArH)), 8.45 (m, 2H, triazole H); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 10.23 (CH<sub>3</sub>), 51.73 (CH<sub>2</sub>), 122.23, 127.64, 127.98, 128.78, 129.93, 130.79, 131.53, 135.58, 139.33, 140.83, 144.10, 151.25, 163.61 (oxadiazole C<sub>2</sub>), 164.02 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 317, 234, 168, 68; CHN Analysis: Calculated for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O: C, 68.09; H, 4.77; N, 22.09. Found C, 68.11; H, 4.75; N, 22.10.

**(d) 1-{{20-(5-Methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl}methyl}piperazine (4d)**- Brown crystals, mp. 135–137 °C; IR (KBr): 3515, 1650 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.07 (s, 3H, CH<sub>3</sub>), 2.74 (t, 4H, piperazine CH<sub>2</sub>), 2.98 (t, 4H, piperazine CH<sub>2</sub>), 3.85 (s, 2H, CH<sub>2</sub>) 7.2–7.62 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 10.77 (CH<sub>3</sub>), 52.79 (HN–CH<sub>2</sub>), 54.80 (–NCH<sub>2</sub>), 62.65 (CH<sub>2</sub>), 127.54, 128.52, 128.97, 129.12, 130.28, 130.82, 131.00, 137.45, 139.07, 141.85, 163.64 (oxadiazole C<sub>2</sub>), 165.43 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 334, 251, 246, 224. 192, 97, 83, 44; CHN Analysis: Calculated for C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O: C, 71.82; H, 6.59; N, 16.79. Found: C, 71.80; H, 6.61; N, 16.80.

**(e) 1-Methyl-4-{{20-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl}methyl}piperazine (4e)**- Pale yellow crystals, mp. 65–66 °C; IR (KBr): 3535, 1665 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.32 (s, 3H, CH<sub>3</sub>), 2.76 (t, 4H, piperazine CH<sub>2</sub>), 2.92 (t, 4H, piperazine CH<sub>2</sub>), 3.80 (s, 4H, CH<sub>2</sub>), 7.55–7.94 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 15.9 (CH<sub>3</sub>), 45.0 (N–CH<sub>3</sub>), 50.7 (CH<sub>2</sub>), 57.8, 64.2, 126.7, 127.0, 127.2, 127.4, 128.3, 128.5, 133.6, 134.0, 135.4, 135.8, 161.5 (oxadiazole C<sub>2</sub>), 168.2 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 348, 265, 249, 192, 98, 44; CHN Analysis: Calculated for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O: C, 72.38; H, 6.92; N, 16.10. Found C, 72.35; H, 6.93; N, 16.11.

**(f) 2-{{4-20-(5-Methyl-1,3,4-oxadiazol-2-yl)-biphenyl}-piperazin-1-yl}ethoxy}ethanol (4f)**- Pale brown crystals, mp. 78–80 °C; IR (KBr): 3515, 3020, 1685 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.08 (s, 3H, CH<sub>3</sub>), 2.44 (t, 4H, piperazine CH<sub>2</sub>), 2.68 (t, 4H, piperazine CH<sub>2</sub>), 2.92 (t, 2H, N–CH<sub>2</sub>), 3.14 (t, 2H, CH<sub>2</sub>O), 3.48 (t, 2H, OCH<sub>2</sub>), 3.74 (t, 2H, CH<sub>2</sub>OH), 3.92 (s, 2H, CH<sub>2</sub>), 7.46–7.75 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 12.0 (CH<sub>3</sub>), 52.6, 53.0, 54.8, 60.4, 61.4, 68.8, 72.4, 126.5, 127.6, 128.5, 128.9, 129.2, 129.7, 129.9, 134.6, 135.2, 135.9, 160.7 (oxadiazole C<sub>2</sub>), 166.7 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 422, 377, 339, 333, 192, 165, 97, 65, 43; CHN Analysis: Calculated for C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>: C, 68.20; H, 7.12; N, 13.30. Found: C, 68.18; H, 7.11; N, 13.29.

**(g) 4-{{20-(5-Methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl}methyl}morpholine (4g)**- Colorless crystals, mp. 60–62 °C; IR (KBr): 3524, 1595 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.07 (s, 3H, CH<sub>3</sub>), 2.34 (t, 4H, morpholine CH<sub>2</sub>), 2.93 (t, 4H, morpholine CH<sub>2</sub>), 3.90 (s, 2H, CH<sub>2</sub>), 7.25–7.96 (m, 8H, ArH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 11.50 (CH<sub>3</sub>), 53.3 (CH<sub>2</sub>), 59.7, 66.8, 127.6, 128.0, 128.2, 128.4, 129.3, 129.4, 134.5, 135.0, 135.1, 135.4, 165.0 (oxadiazole C<sub>2</sub>), 168.7 (oxadiazole C<sub>5</sub>); MS (m/z, 70 eV): 336, 252, 249, 165, 55; CHN Analysis: Calculated for C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.60; H, 6.28, N, 12.57. Found: C, 71.62; H, 6.25, N, 12.55.

**(h) 4-{{20-(5-Methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl}methyl}piperidine-4-carboxylic acid (4h)**- Pale yellow crystals, mp. 68–70 °C; IR (KBr): 3490, 3032–3040, cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.9 (m, 4H, CH<sub>2</sub>), 2.25 (s, 3H, CH<sub>3</sub>), 2.30–2.45 (t, 4H, CH<sub>2</sub>), 3.1 (m, 1H, CH), 3.86 (d, 2H, CH<sub>2</sub>), 7.24–7.53 (m, 8H, ArH), 11.5 (bs, 1H, OH); <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): δ 10.74 (CH<sub>3</sub>), 29.2, 41.7, 51.4 (CH<sub>2</sub>), 60.9, 127.6, 128.5, 128.7, 129.0, 129.8, 130.4, 134.9, 135.6, 136.0, 137.4, 163.9 (oxadiazole C<sub>2</sub>), 167.5 (oxadiazole C<sub>5</sub>), 182.0; MS (m/z, 70 eV): 378, 332, 250, 164, 65, 43; CHN Analysis: Calculated for C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>: C, 70.00; H, 6.10; N, 11.15. Found: C, 70.02; H, 6.08; N, 11.13.

## PHARMACOLOGICAL EVALUATION

**(i) ACE inhibition assay (Jimsheena, 2009; Hooper and Turner, 1987)**- The compounds 3a–3h and 4a–4h were tested at three concentrations viz., 1, 5, and 10 µg, dissolved in assay buffer [10 mM HEPES buffer containing NaCl (0.3 M) and zinc sulfate (10 µM) containing kidney cortex plasma membranes (20 µl, source of ACE) and Hippuryl–His–Leu (1 mM) as substrate. The compounds were incubated with the enzyme for 10 min at 37 °C. The substrate was then added and incubated for 45 min at 37 °C. The reaction was terminated by the addition of HCl (1 M). The yellow color developed by the addition of pyridine (100 µl) and benzenesulphonylchloride (50 µl) was measured at 410 nm in ELISA Plate Reader (iMARK, BIORAD). Compounds with inhibitory potential block the substrate availability to the enzyme and thereby cause enzyme inhibition leading to no formation of yellow color. The inhibition was represented in the form of percentage over control. Captopril, a known ACE inhibitor is used as standard.

**(ii) α -Amylase inhibition assay**- The inhibition assay was performed using the chromogenic DNSA method (Miller, 1959; Sudha et al., 2011). The total assay mixture (sodium phosphate buffer, 0.05 M, 1,400 µl ? α-amylase 50 µl) along with the title compounds 3a–3h and 4a–4h at concentrations 100, 250, and 500 µg were incubated at 37 °C for 10 min. After preincubation starch solution was added to each tube and incubated for 15 min. The reaction was terminated with DNSA reagent, placed on boiling water bath for 5 min, cooled to RT and absorption was measured at 540 nm. The control amylase represented 100 % enzyme activity and do not contain any sample/standard. The maltose liberated was determined by using standard maltose curve. Activities were calculated according to the formula

$$\text{Activity} = \frac{\text{Conc. of maltose liberated} \times \text{vol. of enzyme used (ml)}}{\text{Mol. wt. of maltose} \times \text{incubation time (min)}} \times \text{dilution factor.}$$

The inhibitory property shown by the sample was compared with that of control and expressed as percent induction/inhibition. This was calculated according to the following formula:

$$\% \text{ Activity} = \frac{\text{Activity of enzyme in presence of sample}}{\text{Control activity}} \times 100.$$

## CONCLUSION

At the conclusion of this study, an efficient synthesis of compounds 3a–3h and further ring transformation into 4a–4h involving ring transformation of tetrazole to 1,3,4-oxadiazole ring is described. The inhibition of ACE and  $\alpha$ -amylase enzyme by diverse library of these compounds were also evaluated. It was found that some of the tetrazole derivatives 3b, 3c, 3d, and 3e inhibited the ACE enzyme effectively. Similarly, in case of  $\alpha$ -amylase enzyme inhibition assay, the compounds 3a–3f have inhibited the enzyme and decreased its activity during starch hydrolysis. It is interesting to note that the 1,3,4-oxadiazole derivatives 4a–4h did not show any activity against both the enzymes.

## REFERENCES

- [1]. Amir M, Javed SA, Kumar H (2007) Synthesis of some 1,3,4-oxadiazole derivatives as potential anti-inflammatory agents. *Indian J Chem* 46B:1014–1019
- [2]. Bhaskar VH, Mohite PB (2010) Synthesis, characterization and evaluation of anticancer activity of some tetrazole derivatives. *J Optoelectron Biomed Mater* 2:249–259
- [3]. Chaudhuri SK (1993) *Concise medical physiology*. New Central Book agency (P) Ltd., Calcutta
- [4]. De Souza AO, Pedrosa MT, Alderete JB, Cruz AF, Prado MA, Alves RB, Silva CL (2005) Cytotoxicity, antitumoral and antimycobacterial activity of tetrazole and oxadiazole derivatives. *Pharmazie* 60:396–397
- [5]. El-Emam AA, Al-Deeb OA, Al-Omar M, Lehmann J (2004) Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. *Bioorg Med Chem* 12:5107–5113
- [6]. Emami S, Kebriaeezadeh A, Ahangar N, Khorasani R (2011) Imidazolylchromanone oxime ethers as potential anticonvulsant agents: anticonvulsive evaluation in PTZ-kindling model of epilepsy and SAR study. *Bioorg Med Chem Lett* 21:655–659
- [7]. Farghaly AA, Bekhit AA, Park JY (2000) Design and synthesis of some oxadiazolyl, thiadiazolyl, thiazolidinyl, and thiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents. *Arch Pharm (Weinheim)* 333:53–57
- [8]. Franski R (2005) Biological activities of the compounds bearing 1,3,4-oxa-(thia)-diazole ring. *Asian J Chem* 17:2063–2075
- [9]. Hadizad T, Kirkpatrick SA, Mason S, Burns K, Beanlands RS, Dasilva JN (2009) Novel O-[(11) C]-methylated derivatives of candesartan as angiotensin II AT (1) receptor imaging ligands: radiosynthesis and ex vivo evaluation in rats. *Bioorg Med Chem* 23:7971–7977
- [10]. Haslett C, Chilvers ER, Hunter JAA, Boon NA (1999) *Principles and practice of medicine*. Livingstone, Church Hill
- [11]. Hooper NM, Turner AJ (1987) Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. *Biochem J* 241:625–633
- [12]. Ingole SP, Mohane SR, Berad BN (2007) Synthesis and antimicrobial activity of 2-alkyl-aryl-5-(pyrid-4-yl)-1,3,4-oxadiazole. *Asian J Chem* 19:2683–2686
- [13]. Jimsheena VK (2009) Colorimetric, high-throughput assay for screening angiotensin I converting enzyme inhibitors. *Anal Chem* 81:9388–9394
- [14]. Kagthara PR, Shah NS, Doshi RK, Parekh HH (1999) Synthesis of 2,5-disubstituted-1,3,4-oxadiazoles as biologically active heterocycles. *Indian J Chem* 38B:572–576
- [15]. Khan MSY, Khan RM, Drabu S (2001) Synthesis and antibacterial activity of some 1,3,4-oxadiazole derivatives. *Indian J Heterocycl Chem* 11:119–122
- [16]. Koldobski GI, Ostrovski VA, Popovski VS (1981) Advances in the chemistry of tetrazoles. *Chem Heterocycl Compd* 17:965–989 and the references cited there in
- [17]. Kumar AS, Ghosh S, Mehta GN (2010) Efficient and improved synthesis of Telmisartan. *Beilstein J Org Chem* 6:25. doi:10.3762/bjoc.6.25
- [18]. Larsen RD, King AO, Chen CY, Corley EG, Foster BS, Roberts FE, Yang C, Lieberman DR, Reamer RA (1994) Efficient synthesis of losartan, a nonpeptide angiotensin II receptor antagonist. *J Org Chem* 59:6391–6394
- [19]. Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today* 1:337 and the references cited there in. Accessed 15 June 2012 *J control Rel* 1999,62, 3-6.

- [20]. Maslat AO, Abussaud M, Tashouh H, Al-Talib M (2002) Synthesis, antibacterial, antifungal and genotoxic activity of bis-1,3,4-oxadiazole derivatives. *Pharmacology* 54:55–59
- [21]. Mavromoustakos T, Kolocouris A, Zervou M, Roumelioti P, Matsoukas J, Weisemann R (1999) An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarlesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. *J Med Chem* 42:1714–1722.
- [22]. Meti GY, Kamble RR, Ravi AJ, Arunkashi HK, Devarajegowda HC (2013) 2-[4-(Morpholin-4-ylmethyl)phenyl]benzotrile. *Acta Cryst E* 69:129
- [23]. Miller GL (1959) Use of dinitrosalicylic acid reagent for determination of reducing sugar. *Anal Chem* 31:426–428
- [24]. Mishra A, Singh DV, Mishra RM (2005) Synthesis, antifungal activity of new 1,3,4-oxadiazole[3,2-b]-s-triazine-5-ones and their thione analogues. *Indian J Heterocycl Chem* 14:289–292
- [25]. Mohite PB, Pandhare RB, Khanage SG, Bhaskar VH (2010) Synthesis and anti-inflammatory activity of some 5-phenyl-1-(acyl)-1,2,3,4-tetrazole. *J Pharm Res* 3:43–46
- [26]. Mulwad VV, Rupesh BP, Chaskar Atul C (2008) Synthesis and antibacterial activity of new tetrazole derivatives. *J Korean Chem Soc* 52:249–256
- [27]. Myznikov LV, Hrabalek A, Koldobskii GI (2007) Drugs in tetrazole series. *Chem Heterocycl Compd* 43:1–9
- [28]. O'Neal JB, Rosen H, Russell PB, Adams AC, Blumenthal A (1962) Potential hypoglycemic agents: 1,3,4-oxadiazoles and related compounds. *J Med Chem* 5:617–626
- [29]. Park JH, Chang JS, El-Gamal MI, Choi WK, Lee WS, Chung HJ, Kim H, Cho YJ, Lee BS, Jeon HR, Lee YS, Choi YW, Lee J, Oh CH (2010) Novel amides and esters pro-drugs of olmesartan: synthesis, bioconversion, and pharmacokinetic evaluation. *Bioorg Med Chem Lett* 20:5895–5899
- [30]. Patel JC (1985) Diabetes and its complications. *J Diabet Assoc India* 25:16–25
- [31]. Reddy VM, Reddy PS, Reddy PC, Ratmanc V (1997) Cyclisation by dehydrosulfuration of 1-(2-amino-benzoyl)-4-aryl-3-thiosemicarbazides, formation of 1,3,4-benzotriazepinones, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles. *Indian J Heterocycl Chem* 7:17–20.